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ABSTRACT 
Background:  Better biomarkers must be found to develop clinically useful urine tests for bladder 
cancer.  Proteomics can be used to identify the proteins released by cancer cell lines and generate 
candidate markers for developing such tests.  
Methods:  We used shotgun proteomics to identify proteins released into culture media by 8 
bladder cancer cell lines.  These data were compared with protein expression data from the Human 
Protein Atlas.   EGFR was identified as a candidate biomarker and measured by ELISA in urine from 
60 non-cancer control subjects and from 436 patients with bladder cancer and long-term clinical 
follow-up. 
Results:   Bladder cancer cell lines shed soluble EGFR ectodomain.  Soluble EGFR is also detectable in 
urine and is highly elevated in some patients with high-grade bladder cancer.  Urinary EGFR is an 
independent indicator of poor bladder cancer specific survival with a hazard ratio of 2.89 (95% CI 
1.81-4.62, p<0.001).  In multivariable models including both urinary EGFR and EpCAM both 
biomarkers are independent predictors of bladder cancer specific survival and have prognostic value 
over and above that provided by standard clinical observations.     
Conclusions:  Measuring urinary EGFR and EpCAM may represent a simple and useful approach for 
fast-tracking the investigation and treatment of those patients with the most aggressive bladder 
cancers. 
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INTRODUCTION 
Urothelial bladder cancer (UBC) is the seventh commonest cancer in Western societies (Burger et al, 
2013). At presentation 75-85% will be non-muscle-invasive tumours (NMIBC, stages pTa/pT1/pTis), 
with the remainder being muscle-invasive (MIBC, stages pT2-4) (Kaufman et al, 2009).  Progression 
to, or presentation with, MIBC represents the critical step in the disease course, necessitating radical 
therapies, including chemoradiotherapy or neoadjuvant chemotherapy followed by radical 
cystectomy (Witjes et al, 2014). Despite such approaches, outcomes have changed little for three 
decades (Kaplan et al, 2014). Reliably identifying patients with the most aggressive UBCs early (both 
NMIBC and MIBC) and expediting aggressive therapeutic strategies could go some way to improving 
outcomes (Bryan et al, 2014a), yet this remains a significant challenge despite sophisticated clinico-
pathological algorithms (Babjuk et al, 2013; Witjes et al, 2014).   
Since urine directly contacts UBCs it is an attractive biospecimen for developing non-invasive tests to 
detect and characterise bladder tumours. Challenges in developing such tests include UBC 
heterogeneity, such that different tumours may release different biomarkers (thus necessitating 
multimarker tests), and early-stage and low-grade tumours may only release very small amounts of 
such markers, potentially impairing test sensitivity. Additionally, markers must be highly tumour-
specific so that haematuria and other non-malignant conditions do not generate false positives.  In 
the search for better urinary biomarkers genomic, proteomic and metabolomic approaches have all 
yielded promising results (Huang et al, 2011; Kandimalla et al, 2013; Orenes-Piñero et al, 2007).   
Protein ectodomain shedding is becoming increasingly recognised as an important cancer-related 
phenomenon, and may be a useful source of biomarkers (Hansen et al, 2013; Zatovicova et al, 2005).  
We have previously reported that the ectodomain of EpCAM is shed into the urine by bladder 
tumours (Bryan et al, 2014b).    Here, we use proteomics to identify the proteins released by a panel 
of UBC cells in vitro, and compare them with tissue expression data. One of the shortlisted proteins, 
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EGFR, is released into the urine in a soluble form and is a promising biomarker for rapidly identifying 
UBC patients with the most aggressive disease. This work represents the first description of the 
prognostic value of soluble urinary EGFR in UBC, alone and in combination with soluble urinary 
EpCAM (Bryan et al, 2014b).  
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METHODS 
Materials and samples 
The cell lines used in this study were selected on the basis that they exhibit diverse mutation profiles 
and may capture some of the heterogeneity of UBC (Supplementary Information, Table S1).  Urine 
samples were prospectively collected for biomarker research between 2006 and 2009 as part of the 
Bladder Cancer Prognosis Programme (BCPP, ethics approval 06/MRE04/65) (Zeegers et al, 2010). 
Patients were enrolled on the basis of initial cystoscopic findings suggestive of primary UBC.  All UBC 
patients were newly-diagnosed, had not received treatment for UBC prior to urine collection, and 
were subsequently treated according to current standard practice. Inclusion and exclusion criteria 
are detailed elsewhere (Zeegers et al, 2010). Samples were placed on ice, centrifuged at 2000 x g for 
10 minutes within 8 hours of collection, and supernatants stored at -80°C. Since patient recruitment 
occurred prior to histopathological confirmation of UBC, a proportion of patients were ultimately 
diagnosed with non-malignant conditions and these serve as non-ĐĂŶĐĞƌ ?ĐŽŶƚƌŽůƐ ? ?All patients were 
followed-up to July 2014 with causes of death notified to the BCPP study office.   
 
Proteomic analysis of secretomes 
Cells were grown to >80% confluence (apart from RT4 cells which grow as islands) in 4 x T75 flasks.  
Adherent cells were then washed 4 times with serum-free media and incubated overnight in serum-
free media ± 200nM phorbol 12-myristate 13-acetate (PMA) (2 flasks for each condition equating to 
100-200 µg protein).  The low protein concentration in the conditioned media and the fact that 
>95% of the cells remained adherent indicate that any cell death during secretome generation was 
minimal.   Cells and debris were removed by centrifuging the conditioned media at 2000 x g for 20 
minutes prior and the entire supernatant processed using filter-aided tryptic digestion.  Proteins 
were reduced with 20mM DTT in 8M Urea, 1% CHAPS, 100mM triethylammonium bicarbonate (1 
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hour at room temperature), alkylated with 50mM iodoacetamide and then concentrated in 30 kDa 
centrifugal filters.  Following 4 washes with 100mM triethylammonium bicarbonate, 10 µg of 
sequencing grade trypsin were added to the filters (<50:1 protein:trypsin) and incubated at 37qC 
overnight.  The peptides were centrifuged through the filters and their primary amines dimethylated 
by incubating with 25mM sodium cyanoborohydride and 0.2% formaldehyde (control secretome) or 
0.2% deuterated formaldehyde (+PMA secretome) for 30 min at room temperature.  Following 
quenching with 100mM ammonium bicarbonate the samples were separated into 24 fractions by 
mixed-mode HPLC (Phillips et al, 2010) and each fraction analysed by LC-MS/MS.  For each LC-
MS/MS run peptides were separated using a linear gradient of 1-37% acetonitrile in 0.1% formic acid 
over 1 hour at a flow rate of 350 nl/min (25 cm x 75 µm Acclaim PepMap C18 3µm 100Å column, 
Ultimate 3000 RS HPLC) and sprayed into a maXis impact (Bruker Daltronics) via a captive source 
with the instrument operating in data dependent mode (8 MS/MS per cycle).   The data was 
searched against a database containing Swissprot human and bovine protein sequences and 
randomised versions thereof with MASCOT.  Search parameters were: enzyme = trypsin, up to 2 
missed cleavages, precursor ion tolerance = 20 ppm, fragment ion tolerance = 0.02 Da , mowse score 
>25, fixed modifications = cysteine carbamidomethyl, variable modifications = methionine oxidation 
and light/heavy dimethylation on N-termini and lysines.  Multiple datasets were combined using 
Proteinscape 3 (Bruker Daltronics) and filtered at 1% protein false discovery.  Relative quantitation 
(± PMA) was performed using WARP-LC software (Bruker Daltonics) with expression ratios 
normalised to the median ratio in each experiment.  Cell compartment analysis was performed using 
http://string-db.org/.  
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EGFR ELISA and urine testing 
EGFR was measured with a sandwich ELISA utilising goat polyclonal antibodies against the 
extracellular domain of EGFR (R&D Systems, Cat no. DYC1854-5).  All urine samples were measured 
using 50 µl of urine plus 50 µl of 1% BSA in PBST per well.  Urinary EGFR is expressed as pg EGFR per 
mg creatinine (determined by the Jaffe method).  Cell lysates were prepared in PBS containing 1% 
Igepal CA-630 and Complete Protease Inhibitor Cocktail (Roche) and the protein concentrations 
determined using the bicinchoninic acid assay calibrated with bovine serum albumin.  Secretome 
and lysate EGFR concentrations were determined using appropriate volumes of sample (2-100 µl) for 
the concentration range of the assay.  Secretome and lysate EGFR concentrations are expressed as 
ng EGFR per mg of total cell protein.  For Western blotting proteins were separated with SDS-PAGE 
on 4-12% gels using MOPS running buffer (Life Technologies), blotted onto PVDF probed with 0.2 
µg/ml biotinylated anti-EGFR antibody (R&D Systems, Cat no. BAF231) followed by strepdavidin-HRP. 
 
Human Proteome Atlas analysis    
Data was downloaded from http://www.proteinatlas.org (Uhlen et al, 2010).  For a protein to be a 
candidate biomarker it should be absent or expressed at low levels in normal urothelium and highly 
expressed in UBC; however, due to the heterogeneity of UBC, clinically useful biomarkers may be 
over expressed in a sub-set of tumours rather than in all cases.  We arbitrarily set our selection 
criteria for candidate biomarkers as high or medium staining in at least 4 cases of UBC (out of 11 or 
12 cases depending on the protein) and low or undetectable staining in normal urothelium 
generating a list of 54 proteins.  
 
Statistical Analyses
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Urinary EGFR levels are presented as medians and statistical significance was calculated using 
Mann ?Whitney tests. UBC-specific survival was defined as the time from registration into the BCPP 
study to date of death from UBC. Patients were censored at the date last known to be alive or date 
of UBC-related death.  Univariable Cox proportional hazards models were employed (alpha 0.1) to 
identify factors to be included in a Cox multivariable model; significance was set at 0.05. Univariable 
factors included age (years), tumour number (1 vs 2+), grade (1, 2 vs 3), size of largest tumour (p<3 
cm vs >3 cm), CIS (present vs absent), stage (pTa or pT1 vs pT2+), sex (male vs female), urinary EGFR 
(normal vs elevated) and urinary EpCAM (normal vs elevated).  Analysis was done in Stata 12.1 
(StataCorp, College Station, TX, USA). 
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RESULTS 
Proteomic Analysis of Secretomes 
In total, 2078 unique proteins were identified in the conditioned media of one or more of the UBC 
cell lines with 1338, 1025, 794, 593, 443, 312 and 188 proteins identified in 2, 3, 4, 5, 6, 7 or 8 UBC 
cell lines respectively (Tables 1, S2 and S3).  All secretomes were analysed ± PMA to stimulate 
secretion and shedding.  Relative quantitation was achieved using stable isotope labelling and is 
shown for all proteins quantitated ± PMA in at least 4 UBC cell lines in Figure 1a and Table S4.  The 
cellular compartmentalisation of the 39 proteins with a >2-fold median upregulation in the 
secretomes due to PMA is shown in Figure 1b.  The upregulated proteins are almost exclusively 
secreted and cell surface proteins (34 out of 39 = 87%), whereas the corresponding percentage for 
all proteins found in at least 4 UBC cell lines was 69% and for all proteins found in at least 2 UBC cell 
lines it was 63%.  We found reports of 11 of these proteins previously being investigated as urinary 
biomarkers for UBC with 8 being significantly elevated in patients with UBC (Table S4).   
 
Selection of EGFR as a Candidate Biomarker 
Whilst PMA helps to identify proteins which are genuinely secreted or shed from UBC cells it does 
not necessarily indicate that they are UBC specific, especially as release of the same proteins was 
also stimulated ŝŶƚŚĞŝŵŵŽƌƚĂůŝƐĞĚ ?ŶŽƌŵĂů ?ƵƌŽƚŚĞůŝĂůUROtsa cell line (Table S4).  To address this 
issue we compared the secretome data with immunohistochemistry data in the Human Protein 
Atlas.  This  approach, requiring proteins to be overexpressed in UBC and released from UBC cell 
lines generated a shortlist of 5 candidates (epidermal growth factor receptor or EGFR, glucose-6-
phosphate dehydrogenase, peroxiredoxin 6, LY6/PLAUR domain containing 3 and fibulin 1); EGFR 
was unique in that it was the only one of these 5 proteins that was identified in the cancer cell line 
secretomes and not in the UROtsa secretome.  Tryptic peptides from EGFR were detected in 7 of the 
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8 UBC cell lines with a tendency for more peptides (suggestive of a higher EGFR protein 
concentration) in the cell lines derived from higher grade tumours (Table 1).  ŽƚŚ ?ůŝŐŚƚ ?ĂŶĚ ?ŚĞĂǀǇ ?
EGFR peptides were identified at similar levels in the secretomes indicating that EGFR is released 
into the conditioned media in the absence and presence of PMA.  These findings were confirmed by 
ELISA: all of the cell lines express and release some EGFR although levels range from very low in 
UROtsa and several of the UBC lines through to extremely high in HB-CLS-2.  PMA has a modest 
effect (on average < 2-fold increase) on secretome EGFR levels and the amount of EGFR released 
into the conditioned media varies from cell line to cell line between approximately 1 and 10% of the 
total cellular EGFR.   
Urinary EGFR as a diagnostic marker 
EGFR was measured in the urine of 436 UBC patients and 60 non-cancer controls.  The data are 
summarised in Table 2.  The median urinary EGFR concentration was 153pg/mg creatinine in the 
non-cancer controls and was not significantly increased in patients with pTa UBC.  There were 
significantly higher levels of EGFR in the urine of patients with pT1 or pT2+ UBC (224 and 317pg/mg 
creatinine, respectively).   The data for individual patients stratified according to stage and grade is 
shown in Figure 2.  High levels of urinary EGFR were observed in a proportion, but not all, patients 
with high grade and high stage UBC.    Defining the upper limit of the reference range as the mean + 
2SD in the non-cancer control group gives a threshold of 630 pg EGFR/mg creatinine, and the 
percentage of positive cases is 7, 4, 13, and 27 in non-cancer controls, pTa, pT1 and pT2+ UBC, 
respectively.   
 
Characterisation of ͚ƐŽůƵďůĞ͛ EGFR   
Peptides from the extracellular domain, but not the intracellular domain, of EGFR were identified in 
secretomes from MGH-U3, RT112, 5637, RT-4 and SW-780 cell lines.  VM-CUB-1 and HB-CLS-2 
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secretomes contained the highest levels of EGFR, and peptides from both the intracellular and 
extracellular domains were identified; however, both spectral counting and peptide intensity 
suggested a higher concentration of the extracellular domain than the intracellular domain i.e. the 
extracellular domain of EGFR is shed into the conditioned media but full-length membrane-bound 
EGFR is also present.  To test this hypothesis we ultracentrifuged the secretomes at 136,000 x g for 
90 minutes to pellet membranes and membrane-bound proteins and measured the EGFR remaining 
in the supernatants.  On average, across the secretomes, 73% of the EGFR remained in the 
supernatant confirming that most of the EGFR is a soluble rather than membrane-bound form 
(Figure 3).  Western blotting of the proteins released by HB-CLS-2 cells indicated that the 
predominant form of EGFR in the secretome has a molecular weight of approximately 100 kDa.  A 
small amount of full-length EGFR (approximately 170 kDa) is also present but is removed by 
ultracentrifugation (Figure 3).   
Ultracentrifugation was also used to test whether urinary EGFR was shed extracellular domain or 
membrane-bound EGFR: 12 urine samples with a range of elevated EGFR levels were 
ultracentrifuged and EGFR measured in the supernatants.  On average, 93.5% (SD 7.8%) remained in 
the supernatant, indicating that the predominant form of EGFR in urine is the soluble extracellular 
domain. 
 
Urinary EGFR as a prognostic marker   
Potential prognostic factors (age, number of tumours, grade, size of largest tumour, presence of CIS, 
stage, gender and urinary EGFR) were initially analysed in univariable models.  EGFR was found to be 
highly significant (HR 6.9 90% CI 4.7, 10.1, p<0.001) and this can be seen in the Kaplan-Meier curves 
for UBC-specific survival in both NMIBC and MIBC (Figure 4).  In the univariable analyses grade, 
stage, age, tumour size, CIS and urinary EGFR all reached statistical significance and were included in 
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a multivariable analysis.  The multivariable analysis showed that elevated urinary EGFR has 
prognostic value (HR 2.9 95% CI 1.1, 4.6: P<0.001) over and above that provided by grade and stage 
for UBC-specific survival (Table 3a). 
 
Combination of urinary EpCAM and EGFR for prognostication 
We have previously reported that the urinary concentration of the extracellular domain of EpCAM is 
associated with a shorter UBC-specific survival time (Bryan et al, 2014b).  The urinary concentrations 
of EGFR and EpCAM have quite different distributions in our cohort of UBC patients: many patients 
have high levels of either EpCAM or EGFR (Figure 5) suggesting that they are not-redundant as 
biomarkers and might be used in combination to improve prognostication.  Multivariable modelling 
including both biomarkers and all univariable factors was performed; grade and stage were both 
highly prognostic (p=0.011, p<0.001 respectively), as were EGFR (HR=6.69 95%CI 3.41, 13.12 
p<0.001) and EpCAM (HR=2.13 95%CI 1.19, 3.82 p=0.011). In addition, the interaction between EGFR 
and EPCAM was statistically significant (p=0.001).  It might be predicted that ďĞŝŶŐ ?ĚŽƵďůĞ-ƉŽƐŝƚŝǀĞ ?
(high levels of both biomarkers) would carry an extremely poor prognosis, however, we found this 
not to be the case PĐŽŵƉĂƌĞĚƚŽďĞŝŶŐ ?double-ŶĞŐĂƚŝǀĞ ?(low levels of both biomarkers), the risk of 
death from UBC doubles if a patient is EpCAM high and EGFR low, increases 6.7-fold with high EGFR 
and low EpCAM and ĨŽƌ ?ĚŽƵďůĞ-ƉŽƐŝƚŝǀĞ ?ƚŚĞrisk is increased 2.6-fold. Therefore, although the risk 
associated with being double-positive is greater than only being EpCAM positive it is less than being 
only EGFR positive (p=0.001) (Table 3b and Figure S2).  Utilising the two biomarkers enables the 
identification of a double-negative group of patients who have the best prognosis and those patients 
who are EGFR high and EpCAM low who have the worst prognosis. 
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DISCUSSION 
Combining proteomic analysis of UBC cell line secretomes and immunohistochemistry data available 
in the Human Protein Atlas identified EGFR as a potential urinary biomarker for UBC.  We then 
tested the diagnostic and prognostic utility of urinary EGFR in a cohort of 496 patients with long-
term clinical follow-up.  Urinary EGFR is elevated in 27% of MIBC cases and 17% of grade 3 UBCs but 
normal levels are observed in pTa and low-grade disease; thus, overall, urinary EGFR is not a good 
diagnostic marker for UBC.  However, in patients with confirmed UBC, urinary EGFR is a strong 
independent prognostic indicator of UBC-specific survival.  Urinary EGFR could have utility for rapidly 
identifying patients with the most aggressive disease, and expediting their subsequent investigation 
and management. 
Shedding of EGFR from cancer cell lines (although not UBC cell lines) has been reported to be related 
to overexpression, to be stimulated by PMA (and hence may be under the control of protein kinase 
C), and to be blocked by metalloprotease inhibitors (Perez-Torres et al, 2008). Adamczyk reported 
that pancreatic cancer cell lines release both exosomal (full length, 170 kDa) and ectodomain (110 
kDa) forms of EGFR (Adamczyk et al, 2011).  Evidence suggests that EGFR ectodomain is shed as the 
result of proteolytic cleavage and that it is probably cleavage of an alternatively spliced 3kb 
transcript of EGFR that generates the soluble ectodomain (Wilken et al, 2013).  Although this splice 
variant lacks both the transmembrane and intracellular domains it seems that it remains membrane 
associated until cleaved (Wilken et al, 2013).  Our UBC cell line data is consistent with the body of 
evidence suggesting that both full-length and ectodomain EGFR are released from cancer cells by a 
regulated mechanism involving proteolytic cleavage.  
Soluble EGFR has been detected in plasma and investigated in several cancers (Baron et al, 2003; 
Hudelist et al, 2006; Lemos-González et al, 2007; Müller et al, 2006; Zampino et al, 2008).  However, 
plasma levels appear to be lower in cancer patients than healthy controls, are not related to EGFR 
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expression in tumours and there is little evidence of diagnostic, predictive or prognostic value.  
Although EGF has been measured in the urine of UBC patients (Chow et al, 1997),  the only case of 
EGFR being measured in urine that we have encountered looks at a number of distal tumour sites 
and not UBC (Witters et al, 1995).  Thus, we believe that the current work is the first exploration of 
soluble urinary EGFR as a biomarker for UBC, with a much clearer relationship between urinary EGFR 
and UBC than in studies of plasma EGFR in other solid malignancies.   
EGFR has been reported to be overexpressed in many epithelial cancers and was reported as a poor 
prognostic indicator in UBC as early as 1990 (Neal et al, 1990), representing a late event in the 
progression of the disease (Lipponen & Eskelinen, 1994).  More recently, EGFR overexpression has 
been shown to be a characteristic of basal-like aggressive MIBC, and in mouse models these tumours 
respond to anti-EGFR therapy (Rebouissou et al, 2014).  Several clinical trials using anti-EGFR 
therapies in combination with chemotherapy or radiotherapy in MIBC are currently underway. 
Although further work is required to determine whether urinary levels of EGFR are entirely 
determined by the level of expression in tumour cells, or whether regulation of shedding is also 
important, the fact that many bladder tumours release detectable levels of EGFR into the urine 
suggests that urinary EGFR should be considered as a possible predictive marker in clinical trials 
evaluating anti-EGFR therapy in UBC.  
 
CONCLUSIONS 
We present the first description of the prognostic value of soluble urinary EGFR in UBC, both alone 
and in combination with soluble urinary EpCAM (Bryan et al, 2014b). These ELISA-based tests have 
significant potential clinical utility and we intend to evaluate this potential prospectively in UBC, as 
well as determining whether other urological malignancies also increase urine EGFR levels. 
Mechanisms of ectodomain shedding may add an extra layer of complexity to the molecular 
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pathology of UBC that may not be uncovered by genomic approaches and appear to unmask 
potentially important prognostic markers.  Better understanding of these phenomena may also 
reveal new therapeutic targets, targets that are desperately needed for UBC (Bryan et al, 2014a). 
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Titles and Legends to Tables and Figures 
 
Table 1.  UBC cell line secretome analysis.  The total number of unique peptides identified by LC-
MS/MS in each secretome and the resulting protein identifications are shown alongside the number 
of EGFR peptides identified.  Proteomic analysis was performed once per cell line.  The 
concentration of EGFR (determined by ELISA on biological triplicates) in paired secretomes and cell 
lysates is shown in ng EGFR per mg of cellular protein (determined by BCA assay).  The percentage of 
secreted EGFR (% Sec) is relative to cellular EGFR.  
 
Table 2.  Patient data and urinary EGFR summary.  The total numbers of patients in each stage group 
and the numbers of males and females and number of patients with grade 1, 2 or 3 UBC are shown.  
Age and urinary EGFR for each stage group are shown as median (IQR).  P-values and ROC areas are 
provided for each stage of UBC versus non-cancer controls.  The number of positive cases in each 
group is calculated using a threshold of 630 pg EGFR/mg creatinine (mean + 2 SD of the urinary EGFR 
concentrations in the non-cancer group). 
 
Table 3a. Cox multivariable analysis of prognostic indicators. 
 
Table 3b.  Cox multivariable analysis of prognostic indicators including EpCAM.  
 
Figure 1.  The effect of PMA onUBC cell line secretomes.  Figure 1a shows the log2 of median fold-
change for proteins quantitated in 4 or more UBC cell line secretomes ± PMA (each datapoint is for a 
single protein and the proteins have been sorted fom largest increase to largest decrease): 39 
proteins show a >2-fold increase and 6 protein a >2-fold decrease.  The cell compartment for the 39 
upregulated proteins is shown in Figure 1b.    
 
Figure 2.  Urinary EGFR in UBC patients.  The left hand panel shows urinary EGFR data for patients 
stratified according to stage and the right hand panel according to grade.    
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Figure 3.  The effect of ultracentrifugation on EGFR.  The histogram shows the percentage of EGFR 
remaining in the supernatant following ultracentrifugation.  Secretome data is shown as the mean ± 
SD across all 9 cell lines (± PMA) and urine data as the mean ± SD for urine from 12 patients with 
UBC and elevated EGFR.  The Western blot for shows EGFR in HB-CLS-2 cell lysate and whole (W) and 
ultracentrifuged (U) HB-CLS-2 conditioned media. 
 
Figure 4.  The prognostic value of urinary EGFR.  Kaplan-Meier curves are shown for UBC-specific 
survival with patients stratified according to low/high urinary EGFR (>630 pg/mg creatinine). 
Figure 5.  Relationship between urinary EGFR and EpCAM in UBC: the creatinine-normalised 
concentrations of EGFR and EpCAM in the urine of patients with MIBC. 
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Table 1.   
 
Cell line Grade No. human 
peptides 
No. human 
proteins 
No. EGFR 
peptides 
Secretome  
[EGFR] ng/mg 
Cellular  
[EGFR] ng/mg  
% Sec 
UROtsa NA 5499 763 0 0.40 (0.03), 0.72 (0.08) 43.7 (1.3), 61.4 (3.7) 1.0 
MGH-U3 1 10954 1041 5 4.29 (0.92), 4.46 (1.19) 90.8 (4.7), 94.7 (8.9) 4.7 
R-T4 1 8145 1160 1 1.30 (0.36), 2.62 (0.29) 34.0 (18.0), 22.1 (11.8) 9.6 
SW-780 1 4181 627 1 2.81 (0.32), 4.11 (0.62) 49.3 (4.50), 62.2 (16.7) 5.9
RT112 2 5900 787 4 0.66 (0.07), 1.18 (0.17) 82.4 (3.3), 62.0 (5.6) 1.3 
VM-CUB-1 2 5915 765 16 10.8 (2.39), 9.40 (1.18) 227 (3.79), 151 (41.7) 5.5 
5637 2 4188 628 3 0.41 (0.03), 0.68 (0.04) 102 (3.81), 72.8 (0.87) 0.7 
T-24 3 7087 916 0 1.19 (0.32), 2.37 (0.57) 27.1 (1.36), 29.0 (3.18) 6.3
HB-CLS-2 3 7135 847 53 252 (92.8), 298 (22.3) 2720 (161), 2646 (927) 10.3
 
  
 
Table 2.   
Stage n Male/Fe
male 
Grade
(G1/G2/G3) 
Age EGFR
(pg/mg creatinine) 
p-value 
 
ROC No. positive 
cases 
Non-cancer 60 45/15 na 75 (66-79) 153 (91-261) na na 4 (7%)
pTa 184 140/44 79/84/21 74 (65-81) 167 (124-236) 0.395 0.536 3 (2%)
pT1 130 112/18 2/37/91 75 (67-80) 224 (151-353) 0.0003 0.650 13 (10%)
pT2+ 122 97/25 0/6/116 78 (68-83) 317 (215-658) 0.0001 0.766 33 (27%)
 
 
 Table 3a.  
 
Variable ɴ Se(ɴ) Haz Ratio P-value HR 95% CI 
Grade 3 (reference grade 1 or 2) 0.982 0.395 2.670 0.013 1.231, 5.792
Stage pT2+ (reference pTa or pT1) 1.997 0.306 7.369 <0.001 4.043, 13.429 
High EGFR (reference low EGFR) 1.062 0.239 2.891 <0.001 1.809, 4.620 
 
 
Table 3b.   
Variable ɴ Se(ɴ) Haz Ratio P-value HR 95% CI 
Grade 3 (reference grade 1 or 2) 1.005 0.394 2.732 0.011 1.262, 5.912
Stage pT2+ (reference pTa or pT1) 1.892 0.301 6.632 <0.001 3.680, 11.953 
High EGFR (reference low EGFR) 1.900 0.344 6.691 <0.001 3.411, 13.124 
High EpCAM (reference low EpCAM) 0.756 0.298 2.131 0.011 1.189, 3.818 
EGFR and EpCAM Interaction 
(High EGFR and EpCAM) 
-1.689 0.487 0.185 0.001 0.071, 0.480 
 
 
 
